- Home
- SGC vs CNTX Comparison
SGC vs CNTX Comparison
Compare SGC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGC | CNTX |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.5M | 132.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGC | CNTX |
|---|---|---|
| Price | $9.95 | $1.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $17.33 | $6.00 |
| AVG Volume (30 Days) | 41.3K | ★ 1.6M |
| Earning Date | 03-10-2026 | 11-05-2025 |
| Dividend Yield | ★ 5.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $565,017,000.00 | N/A |
| Revenue This Year | $0.73 | N/A |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | $28.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.30 | $0.49 |
| 52 Week High | $16.38 | $2.00 |
Technical Indicators
Market Signals| Indicator | SGC | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 54.71 |
| Support Level | $9.18 | $1.46 |
| Resistance Level | $10.45 | $1.65 |
| Average True Range (ATR) | 0.31 | 0.18 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 60.30 | 33.44 |
Price Performance
Historical ComparisonAbout SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.